Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) September 30, December 31, 2023 2022 $ $ Assets Current assets Cash 33,625 46,517 Trade and other receivables (note 3) 6,619 6,344 Inventory (note 4) 7,425 7,941 Prepaid expenses and deposits 648 1,222 Total current assets 48,317 62,024 ...

财务数据和关键指标变化 - 公司第二季度录得收入1.6百万美元,全部来自经常性收入,较2022年同期增长38% [14] - 总运营费用为7.5百万美元,较2022年同期下降14% [15] - 研发费用为3.2百万美元,下降14% [16] - 管理费用下降21%至2.1百万美元 [16] - 销售及分销费用下降6%至2.3百万美元 [16] - 净亏损为7.4百万美元,每股亏损0.35美元,较2022年同期增加 [17] - 截至6月30日,公司净现金为39.3百万美元 [17] 各条业务线数据和关键指标变化 - 美国经常性收入较第一季度增长21%,较2022年上半年增长63% [22] - 公司预计2023年美国业务收入将增长约70% [22] - 70%的患者为自付费用,每例平均支付超过3万美元 [23] 各个市场数据和关键指标变化 - 公司正在积极投资美国市场,而非国际市场 [31] - 预计2023年下半年日本等重要市场的安装基数将有所增加 [31] 公司战略和发展方向及行业竞争 - 公司已获得美国医疗协会(AMA)批准的3个TULSA新的1类CPT编码,将于2025年1月1日生效 [25][26] - 公司计划到2023年底安装50台TULSA系统,2024年底达到至少75台 [29][44] - 公司认为TULSA的总可用市场约为60万例,大于任何其他治疗前列腺疾病的技术 [35] - 公司认为2025年第一季度CAPTAIN临床试验初步结果和永久性报销编码的建立将成为TULSA在美国的重要催化剂 [46] 管理层对经营环境和未来前景的评论 - 公司未受到宏观环境的重大影响,管理层对管道和未来增长持乐观态度 [65] - 公司正在与MRI设备公司进行沟通,未来可能会看到更多合作 [93][94] - 公司认为门诊手术中心(ASC)可能成为TULSA的重要应用场景 [98][99][100][101] 其他重要信息 - TACT临床试验5年随访结果显示TULSA治疗的安全性、有效性和功能性结果在5年内保持稳定 [36][37][38][39][40] - 公司正在开发TULSA AI系统,预计将于明年推出,有望进一步提高治疗效果 [86][87] 问答环节重要的提问和回答 问题1 **Rahul Sarugaser 提问** 询问公司2023年底安装50台系统的目标是否可实现,以及CPT编码获批后是否看到医院和医生的兴趣增加 [49][50] **Arun Menawat 回答** 公司正在看到更多医生对TULSA感兴趣,CPT编码的获批正在推动管道的增长 [51][52] 问题2 **Nelson Cox 提问** 询问公司在MRI使用时间方面是否仍存在挑战 [69][70] **Arun Menawat 回答** 公司已经解决了MRI使用时间的问题,现在可以兼容多种MRI设备 [70][71] 问题3 **Ben Haynor 提问** 询问公司毛利率提升至75%以上的可能性,以及未来的研发计划 [79][80][81][86][87] **Arun Menawat 回答** 公司有信心未来随着产品量增加,毛利率可以提升至75%以上,正在开发TULSA AI系统以进一步提升治疗效果 [80][81][86][87]

Profound Medical Corp. (NASDAQ:PROF) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO and Chairman Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Ben Haynor - Alliance Global Partners Joshua Jennings - TD Cowen Frank Takkinen - Lake Street Capital Markets Brian Gagnon - Gagnon Securities Operator Good day and thank you for standing by. Welcome to the Profound Medical First Quarter ...

Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) December June 30, 31, 2023 2022 $ $ Assets Current assets Cash 39,275 46,517 Trade and other receivables (note 3) 6,586 6,344 Inventory (note 4) 8,056 7,941 Prepaid expenses and deposits 776 1,222 Total current assets 54,693 62,024 ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer and Chairman Rashed Dewan – Chief Financial Officer Conference Call Participants Michael Sarcone – Jefferies Rahul Sarugaser – Raymond James Ben Haynor – Alliance Frank Takkinen – Lake Street Brian Gagnon – Gagnon Securities Scott McAuley – Paradigm Capital Operator Good day and thank you for standing by. Welcome to the ...

Incision-Free Ablative Intervention, With Vision Profound Corporate Presentation | March 2023 © 2023 Profound Medical Corp. NASDAQ: PROF TSX: PRN Forward-Looking Information Certain statements in this presentation may contain certain information that is "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws with respect to Profound Medical Corp. ("Profound" or the "Company"). Such statements include all statements other than statements of historical fa ...

EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full y ...

Profound Medical Corp. (NASDAQ:PROF) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Michael Sarcone - Jefferies Rahul Sarugaser - Raymond James Brian Gagnon - Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical Incorporated Third Quarter 2022 Conference Call. [Operator Instructions] Please be advised that today's conference is being reco ...

Profound Medical Corp. (NASDAQ:PROF) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Zach Weiner - Jefferies Rahul Sarugaser - Raymond James Operator Welcome to the Profound Medical Second Quarter 2022 Financial Results Conference Call. My name is Darryl, and IÂ'll be your operator for todayÂ's call. [Operator Instructions] I will now turn the ...

Profound Medical Corp. (NASDAQ:PROF) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Dr. Arun Menawat – Chief Executive Officer and Chairman of the Board Rashed Dewan – Chief Financial Officer Stephen Kilmer – Investor Relations Conference Call Participants Rahul Sarugaser – Raymond James Frank Takkinen – Lake Street Capital Markets Josh Jeggings – Cowen and Company Scott McAuley – Paradigm Capital Brian Gagnon – Gagnon Securities Operator Good day, and thank you for standing by ...